These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19184676)

  • 21. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mass spectrometry analysis of new chemical entities for pharmaceutical discovery.
    Fang AS; Miao X; Tidswell PW; Towle MH; Goetzinger WK; Kyranos JN
    Mass Spectrom Rev; 2008; 27(1):20-34. PubMed ID: 18033735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of lipophilicity in drug discovery and design.
    Arnott JA; Planey SL
    Expert Opin Drug Discov; 2012 Oct; 7(10):863-75. PubMed ID: 22992175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive approaches to increase absorption of compounds during lead optimisation.
    Valko K; Butler J; Eddershaw P
    Expert Opin Drug Discov; 2013 Oct; 8(10):1225-38. PubMed ID: 23865945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipophilicity and biomimetic properties to support drug discovery.
    Tsopelas F; Giaginis C; Tsantili-Kakoulidou A
    Expert Opin Drug Discov; 2017 Sep; 12(9):885-896. PubMed ID: 28644732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipophilicity--methods of determination and its role in medicinal chemistry.
    Rutkowska E; Pajak K; Jóźwiak K
    Acta Pol Pharm; 2013; 70(1):3-18. PubMed ID: 23610954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Increasing the solubility and permeability of pharmacons with pharmaceutical technological methods].
    Aigner Z
    Acta Pharm Hung; 2008; 78(1):3-10. PubMed ID: 18476363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A strategy to reduce biliary clearance in early drug discovery.
    Rioux N; Bellavance E; Poirier H; Dupuis M; Garneau M; Ribadeneira MD; Duan J
    J Pharmacol Toxicol Methods; 2013; 68(3):346-8. PubMed ID: 23518065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular design for enhancement of ocular penetration.
    Shirasaki Y
    J Pharm Sci; 2008 Jul; 97(7):2462-96. PubMed ID: 17918725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space.
    Vallianatou T; Giaginis C; Tsantili-Kakoulidou A
    Adv Exp Med Biol; 2015; 822():187-94. PubMed ID: 25416989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview on the Rule of Five.
    Pollastri MP
    Curr Protoc Pharmacol; 2010 Jun; Chapter 9():Unit 9.12. PubMed ID: 22294375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery.
    Parrott N; Paquereau N; Coassolo P; Lavé T
    J Pharm Sci; 2005 Oct; 94(10):2327-43. PubMed ID: 16136543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies.
    Sköld C; Winiwarter S; Wernevik J; Bergström F; Engström L; Allen R; Box K; Comer J; Mole J; Hallberg A; Lennernäs H; Lundstedt T; Ungell AL; Karlén A
    J Med Chem; 2006 Nov; 49(23):6660-71. PubMed ID: 17154497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excipient pharmacokinetics and profiling.
    Loftsson T
    Int J Pharm; 2015 Mar; 480(1-2):48-54. PubMed ID: 25596414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High throughput solubility measurement in drug discovery and development.
    Alsenz J; Kansy M
    Adv Drug Deliv Rev; 2007 Jul; 59(7):546-67. PubMed ID: 17604872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery pharmaceutics--challenges and opportunities.
    Chen XQ; Antman MD; Gesenberg C; Gudmundsson OS
    AAPS J; 2006 Jun; 8(2):E402-8. PubMed ID: 16796392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.